Thomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.
Thomas R. Chauncey, MD, PhD, associate professor, Department of Medical Oncology, University of Washington School of Medicine, associate member, Fred Hutchinson Cancer Research Center, medical oncologist, Seattle Cancer Care Alliance, discusses the phase 3 ICARIA-MM trial (NCT02990338) and IKEMA (NCT03275285) trials with isatuximab-irfc (Sarclisa) combinations in patients with relapsed or refractory multiple myeloma.
The ICARIA-MM trial evaluated isatuximab plus carfilzomib (Kyprolis) and dexamethasone, and the IKEMA study evaluated isatuximab with pomalidomide (Pomalyst) in this patient population. Both trials demonstrated that the regimens were efficacious, and the agents have been incorporated into standard regimens for patients with relapsed or refractory multiple myeloma, according to Chauncey.
Notably, the outcomes for patients were slightly different between the trials, and cross-trial comparisons should be avoided, Chauncey notes. Moreover, the eligibility criteria show a difference in risk between the 2 trials, Chauncey adds. Despite these differences, the regimens represent feasible treatment options for this patient population, Chauncey concludes.